In this episode, the editorial team had the opportunity to speak with Dr. Brett Wingeier, CEO of neuromodulation MedTech company Magnus Medical about the company’s Magnus System for the treatment of major depressive disorder (MDD). The neurostimulation device received breakthrough device designation from the US Food and Drug Administration (FDA) last month. The team heard from Dr. Wingeier about the challenges of treating depression and how neuromodulation shows clinical effectiveness for patients. Given this, he explained how the company decided to develop the Magnus System and described how it works. As a 20-year veteran in the field of neuromodulation, hear Dr. Wingeier’s insights into how the field continues to grow. 

Read the full article here: 

Magnus Medical’s Neurostimulation Technology Granted FDA Breakthrough Device Designation 

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks